Back to News
May 19, 2026 4:00 PM

ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies

ImmunityBio Inc. (NASDAQ:IBRX) presented two indirect treatment comparison analyses, highlighting efficacy and safety outcomes for ANKTIVA plus Bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary disease.

ImmunityBio Presents Comparative ANKTIVA Data

The presentations compared ANKTIVA (nogapendekin alfa inbakicept-pmln) combined with BCG against two FDA-approved therapies, Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firadenovec-vncg) and Johnson & Johnson’s (NYSE:JNJ) INLEXZO (TAR-200).

Read Also:

ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership

ANKTIVA Combo Showed Higher Response Rates Against Nadofaragene

In one matching-adjusted indirect comparison, ImmunityBio evaluated ...